Compare · ALZN vs PRTA

ALZN vs PRTA

Side-by-side comparison of Alzamend Neuro Inc. (ALZN) and Prothena Corporation plc (PRTA): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both ALZN and PRTA operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
  • PRTA is the larger of the two at $419.0M, about 70.0x ALZN ($6.0M).
  • PRTA has been more active in the news (10 items in the past 4 weeks vs 1 for ALZN).
  • PRTA has more recent analyst coverage (22 ratings vs 1 for ALZN).
MetricALZNPRTA
Company
Alzamend Neuro Inc.
Prothena Corporation plc
Price
-
-
Market cap
$6.0M
$419.0M
1M return
-
-
1Y return
-
-
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Exchange
NASDAQ
NASDAQ
IPO
2021
News (4w)
1
10
Recent ratings
1
22
ALZN

Alzamend Neuro Inc.

Alzamend Neuro, Inc., a preclinical stage biopharmaceutical company, focuses on developing products for the treatment of neurodegenerative diseases and psychiatric disorders. The company's lead product candidate is AL001 for the treatment of Alzheimer's and other neurodegenerative diseases and psychiatric disorders. It is also developing AL002, a cell-based therapeutic vaccine, which seeks to restore the ability of the patient's immunological system to Alzheimer's. The company was incorporated in 2016 and is headquartered in Tampa, Florida.

PRTA

Prothena Corporation plc

Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing PRX002/RG7935 that is in Phase 2 clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, an antibody that is in Phase 1 clinical trial for the treatment of ATTR amyloidosis. Its discovery-stage programs include Tau for treating Alzheimer's disease, frontotemporal dementia, progressive supranuclear palsy, chronic traumatic encephalopathy, and other tauopathies; Aß, or Amyloid Beta, a protein for the treatment of Alzheimer's disease; TDP-43 for amyotrophic lateral sclerosis and frontotemporal dementia; and other products for neurodegenerative diseases. The company has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. Prothena Corporation plc was founded in 2012 and is based in Dublin, Ireland.

Latest ALZN

Latest PRTA